SLS - SELLAS Life Sciences Group, Inc.
IEX Last Trade
0.92
0.013 1.457%
Share volume: 1,190,446
Last Updated: Mon 13 Jan 2025 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.38%
PREVIOUS CLOSE
CHG
CHG%
$0.91
-0.03
-0.03%
View ratios
| Fiscal Date | 2024-03-31 | 2024-06-30 | 2024-09-30 | |
|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | |
| Report Date | 2024-05-14 | 2024-08-13 | 2024-11-13 | |
| Assets | ||||
| Total Assets | 24.434 M | 15.119 M | 26.505 M | |
| Current Assets | 21.501 M | 12.302 M | 24.035 M | |
| Inventories | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 0.000 | 0.000 | 0.000 | |
| Total Receivables | 0.000 | 0.000 | 0.000 | |
| Current Cash | 18.415 M | 9.147 M | 21.031 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 0.000 | 0.000 | 0.000 | |
| Other Assets | 2.933 M | 2.817 M | 2.470 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||
| Total Liabilities and shareholders’ equity | 24.434 M | 15.119 M | 26.505 M | |
| Total liabilities | 14.750 M | 12.206 M | 10.613 M | |
| Total current liabilities | 14.437 M | 12.045 M | 10.613 M | |
| Accounts Payable | 7.407 M | 6.331 M | 4.547 M | |
| Other liabilities | 313.000 K | 161.000 K | 0.000 | |
| Current long term debt | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 313.000 K | 161.000 K | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 9.684 M | 2.913 M | 15.892 M | |
| Common stock | 236.494 M | 237.193 M | 257.280 M | |
| Retained earnings | -226.810 M | -234.280 M | -241.388 M |